Document registry — page 38
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in obesity randomising 605 participants over 32 weeks. Primary result: Dose-dependent weight…
31 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low30 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low27 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low27 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low26 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low25 Jul 2023 -
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 295 participants over 30 weeks. Primary result: Superior glycaemic…
High24 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Single-arm open-label, phase 1 study of Ipamorelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low22 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low19 Jul 2023 -
Randomised crossover, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low19 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low18 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity randomising 2,254 participants over 160 weeks. Primary result…
Moderate17 Jul 2023 -
Randomised crossover, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jul 2023 -
Observational, phase 3 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Jul 2023 -
Sustained elevation of arterial pressure above accepted diagnostic thresholds, considered here as a weight-responsive outcome rather than a primary treatment indication.
13 Jul 2023 -
Observational, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low13 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low13 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low10 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Jul 2023 -
An adverse lipoprotein profile, typically raised triglycerides with reduced HDL cholesterol and a raised apolipoprotein B to apolipoprotein A1 ratio.
09 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Jul 2023 -
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 911 participants over 26 weeks. Primary result: Did not meet…
High08 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low07 Jul 2023 -
Observational, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low07 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and obesity randomising 529 participants over 52 weeks. Primary result: Clinical…
Moderate05 Jul 2023 -
Randomised crossover, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Jul 2023 -
Observational, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low04 Jul 2023
page 38 of 41